Enzyme-linked immunosorbent assay

The enzyme-linked immunosorbent assay is a serological screening tool central to the diagnosis of hepatitis C virus infection. It detects anti-HCV antibodies, but antibody positivity alone does not establish that the virus is still replicating: active chronic infection requires both anti-HCV positivity and detectable HCV RNA. This distinction makes the assay a gateway to diagnosis rather than a complete definition of current disease.

Diagnostic Role and Limits

The diagnosis of HCV infection begins with detection of anti-HCV antibodies using third-generation enzyme-linked immunosorbent assay systems. A positive result indicates an immune response to HCV, but it cannot by itself distinguish resolved infection from chronic infection. That distinction depends on whether HCV RNA is detectable in serum through a sensitive molecular assay, whose threshold is approximately 15 IU/ml. Chronic infection is therefore established by the combination of anti-HCV and HCV RNA positivity.

The antibody assay is consequently paired with nucleic acid testing rather than treated as a stand-alone diagnosis. A person may retain anti-HCV antibodies after recovery, whereas detectable HCV RNA indicates active infection. The separation between serological evidence of exposure and molecular evidence of viral persistence is especially important when treatment, monitoring, or assessment of extrahepatic disease is being considered.

Screening Before Kidney Transplantation

The assay has a defined place in screening candidates for kidney transplantation. In geographical regions with low HCV prevalence, recommended practice begins with an enzyme immunoassay; candidates who test anti-HCV positive then undergo confirmatory nucleic acid testing to document viremia. In settings with high HCV prevalence, nucleic acid testing should be used as the first-line screen because a negative antibody assay cannot reliably exclude infection.

This strategy reflects the concealed burden of liver disease in the transplant population. Up to one quarter of patients found to have active HCV infection have advanced liver fibrosis on liver biopsy, even though their liver disease is usually well compensated and would not otherwise be suspected. Screening therefore does more than label prior exposure: when followed by molecular confirmation and assessment of fibrosis, it can uncover clinically important disease before transplantation.

Interpretation in Systemic Disease

The assay also frames evaluation of HCV as a systemic infection rather than a disorder confined to the liver. HCV can produce autoimmune, dermatological, and renal disease, including mixed cryoglobulinemia and cryoglobulinemic glomerulonephritis. In mixed cryoglobulinemia, cryoglobulins are essential to diagnosis and HCV RNA is usually present in serum; kidney manifestations may include proteinuria, hematuria, reduced estimated glomerular filtration rate, nephritic syndrome, or nephrotic syndrome. Anti-HCV antibody detection can identify the underlying infection, but it does not by itself establish the mechanism or severity of these renal syndromes.

The same boundary remains important in transplant medicine. HCV-infected renal and liver allograft recipients may develop immune complex-mediated glomerulonephritis, including de novo membranoproliferative glomerulonephritis associated with type II mixed cryoglobulinemia. In such patients, HCV RNA is often much higher in the cryocrit than in serum, and very low cryocrit levels can limit detection and characterization of cryoglobulins. The antibody assay contributes to identifying HCV exposure, while molecular and pathological investigations determine whether active viral infection and immune-complex injury are present.

Epidemiological and Clinical Context

The importance of reliable serological screening grew as HCV became recognized as the major cause of non-A, non-B hepatitis and as a persistent problem in chronic kidney disease, dialysis, and transplantation. In long-term dialysis populations, anti-HCV positivity has been associated with reduced survival. A meta-analysis of seven observational studies including 11,589 dialysis patients estimated an adjusted relative risk for all-cause mortality of 1.34, while liver-related mortality was substantially higher among anti-HCV-positive patients, with an unadjusted relative risk estimate of 5.89. These findings concern serological status, but they do not erase the diagnostic distinction between antibody positivity and active viremia.

The assay must also be understood within changing patterns of transmission and prevention. In the early 1990s, dialysis patients had high HCV prevalence, reflecting both transfusion exposure and suspected nosocomial transmission within hemodialysis units. As blood-donor screening improved and erythropoiesis-stimulating agents reduced the need for transfusion, the estimated risk of post-transfusion hepatitis C in the United States fell from about 0.5% per blood unit in the 1980s to approximately 0.0001%, or one case per million blood units. Serological testing thus became part of a broader system of surveillance and infection control rather than an isolated laboratory procedure.

Place in the Diagnostic Pathway

The enzyme-linked immunosorbent assay is best understood as the first interpretive layer in a staged pathway. Anti-HCV positivity prompts confirmation of viremia, while evaluation of active chronic infection requires attention to both hepatic and extrahepatic effects. Liver injury may be assessed by biopsy or noninvasive methods such as FibroScan, and the patient may also require evaluation for cryoglobulinemia-associated vasculitis and renal disease.

That sequence prevents two opposite errors: dismissing a positive antibody result as proof of current viral replication, or dismissing a negative antibody result as definitive in a high-prevalence setting. Its significance lies precisely in this disciplined limitation. The assay makes exposure visible, but HCV RNA, fibrosis assessment, clinical findings, and—when necessary—renal pathology determine what that exposure means for the individual patient.